Overview

This is a summary of the European public assessment report (EPAR) for Votrient. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Votrient.

Votrient is a medicine that contains the active substance pazopanib. It is available as tablets (200 mg; 400 mg).

Votrient is used to treat adults with the following types of cancer:

  • advanced renal-cell carcinoma, a type of kidney cancer. It is used in patients who have not received any previous treatment or in patients who have already been treated for their advanced disease with anticancer medicines called ‘cytokines’. ‘Advanced’ means that the cancer has started to spread;
  • certain forms of soft-tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the body. It is used in patients who have been previously treated with chemotherapy (medicines to treat cancer) because their cancer had spread, or in patients whose cancer has progressed within 12 months after receiving adjuvant or neoadjuvant therapy (treatment received after or before their main treatment).

The medicine can only be obtained with a prescription.

Treatment with Votrient should only be started by a doctor who has experience in giving anticancer medicines. The recommended dose is 800 mg once a day, but this may need to be reduced if the patient has side effects. Votrient should be taken with water but without food, at least one hour before or two hours after a meal.

In patients with moderate liver problems the dose should be reduced to 200 mg once a day. Votrient is not recommended in patients with severe liver problems.

The active substance in Votrient, pazopanib, is a protein-kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found in some receptors on the surface of cells that are involved in the growth and spread of cancer cells, such as ‘VEGFR’, ‘PDGFR’ and ‘KIT’. By blocking these enzymes, Votrient can reduce the growth and spread of the cancer.

Votrient has been compared with placebo (a dummy treatment) in one main study involving 435 patients with advanced renal-cell carcinoma, some of whom had previously been treated with cytokines. Votrient has also been compared with placebo in a main study involving 369 patients with soft-tissue sarcoma whose disease had progressed during or following previous chemotherapy.

In all of the studies, the main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).

Votrient was more effective than placebo at treating advanced renal-cell carcinoma. On average, the patients who took Votrient lived for 9.2 months without their disease getting worse, compared with 4.2 months for the patients who took placebo.

Votrient was also more effective than placebo at treating soft-tissue sarcoma. On average, the patients who took Votrient lived for 20 weeks without their disease getting worse, compared with seven weeks for the patients who took placebo.

The most common side effects with Votrient (seen in more than 1 patient in 10) include reduced appetite, dysgeusia (taste disturbances), hypertension (high blood pressure), diarrhoea, nausea (feeling sick), vomiting, pain, hair colour change, fatigue (tiredness), skin hypopigmentation (discolouration of the skin), exfoliative (flaky) rash, headache, stomatitis (inflammation of the lining of the mouth), decreased weight and increased blood levels of certain liver enzymes. For the full list of all side effects reported with Votrient, see the package leaflet.

Votrient must not be used in people who are hypersensitive (allergic) to pazopanib or any of the other ingredients.

The CHMP considered that Votrient has been shown to be an effective medicine for patients with advanced renal-cell carcinoma and soft-tissue sarcoma, with a clinically relevant improvement in progression-free survival. The safety profile of Votrient is considered acceptable and generally manageable. Therefore, the Committee decided that Votrient’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Votrient was originally given ‘conditional approval’ because there was more evidence to come about the medicine, in particular in the treatment of renal-cell carcinoma. As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.

The European Commission granted a conditional marketing authorisation valid throughout the European Union for Votrient on 14 June 2010. This was switched to a full marketing authorisation on 1 July 2013.

For more information about treatment with Votrient, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

български (BG) (139.35 KB - PDF)

View

español (ES) (110.89 KB - PDF)

View

čeština (CS) (137.18 KB - PDF)

View

dansk (DA) (108.37 KB - PDF)

View

Deutsch (DE) (87.58 KB - PDF)

View

eesti keel (ET) (109.56 KB - PDF)

View

ελληνικά (EL) (140.42 KB - PDF)

View

français (FR) (111.67 KB - PDF)

View

italiano (IT) (108.93 KB - PDF)

View

latviešu valoda (LV) (119.96 KB - PDF)

View

lietuvių kalba (LT) (111.72 KB - PDF)

View

magyar (HU) (132.36 KB - PDF)

View

Malti (MT) (138.63 KB - PDF)

View

Nederlands (NL) (110.51 KB - PDF)

View

polski (PL) (137.13 KB - PDF)

View

português (PT) (109.37 KB - PDF)

View

română (RO) (133.97 KB - PDF)

View

slovenčina (SK) (135.29 KB - PDF)

View

slovenščina (SL) (128.75 KB - PDF)

View

Suomi (FI) (109.89 KB - PDF)

View

svenska (SV) (110.53 KB - PDF)

View

Product information

български (BG) (692.89 KB - PDF)

View

español (ES) (547.08 KB - PDF)

View

čeština (CS) (634.31 KB - PDF)

View

dansk (DA) (600.13 KB - PDF)

View

Deutsch (DE) (566.51 KB - PDF)

View

eesti keel (ET) (511.11 KB - PDF)

View

ελληνικά (EL) (760 KB - PDF)

View

français (FR) (683.61 KB - PDF)

View

hrvatski (HR) (632.77 KB - PDF)

View

íslenska (IS) (538.27 KB - PDF)

View

italiano (IT) (679.42 KB - PDF)

View

latviešu valoda (LV) (794.06 KB - PDF)

View

lietuvių kalba (LT) (708.73 KB - PDF)

View

magyar (HU) (623.93 KB - PDF)

View

Malti (MT) (640.6 KB - PDF)

View

Nederlands (NL) (542.42 KB - PDF)

View

norsk (NO) (543 KB - PDF)

View

polski (PL) (660.46 KB - PDF)

View

português (PT) (532.77 KB - PDF)

View

română (RO) (655.9 KB - PDF)

View

slovenčina (SK) (657.46 KB - PDF)

View

slovenščina (SL) (630.56 KB - PDF)

View

Suomi (FI) (567.02 KB - PDF)

View

svenska (SV) (536.9 KB - PDF)

View

Latest procedure affecting product information: N/0075

20/04/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (50.03 KB - PDF)

View

español (ES) (102.71 KB - PDF)

View

čeština (CS) (38.42 KB - PDF)

View

dansk (DA) (14.94 KB - PDF)

View

Deutsch (DE) (15.09 KB - PDF)

View

eesti keel (ET) (12.97 KB - PDF)

View

ελληνικά (EL) (27 KB - PDF)

View

français (FR) (17.26 KB - PDF)

View

íslenska (IS) (49.19 KB - PDF)

View

italiano (IT) (46.17 KB - PDF)

View

latviešu valoda (LV) (56.64 KB - PDF)

View

lietuvių kalba (LT) (26.46 KB - PDF)

View

magyar (HU) (29.84 KB - PDF)

View

Malti (MT) (38.51 KB - PDF)

View

Nederlands (NL) (43.8 KB - PDF)

View

norsk (NO) (15.9 KB - PDF)

View

polski (PL) (36.29 KB - PDF)

View

português (PT) (50.66 KB - PDF)

View

română (RO) (34.98 KB - PDF)

View

slovenčina (SK) (51.4 KB - PDF)

View

slovenščina (SL) (76.6 KB - PDF)

View

Suomi (FI) (47.02 KB - PDF)

View

svenska (SV) (26.1 KB - PDF)

View

Product details

Name of medicine
Votrient
Active substance
pazopanib
International non-proprietary name (INN) or common name
pazopanib
Therapeutic area (MeSH)
Carcinoma, Renal Cell
Anatomical therapeutic chemical (ATC) code
L01XE11

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Renal-cell carcinoma (RCC)

Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

Soft-tissue sarcoma (STS)

Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.

Efficacy and safety have only been established in certain STS histological tumour subtypes.

Authorisation details

EMA product number
EMEA/H/C/001141
Marketing authorisation holder
Novartis Europharm Limited 

Vista Building
Elm Park
Merrion Road
Dublin 4
D04 A9N6 
Ireland

Opinion adopted
14/06/2010
Marketing authorisation issued
14/06/2010
Revision
31

Assessment history

Topics

This page was last updated on

How useful do you find this page?